Skip to main content

Healthy Adult Female Participants

4
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
2
0
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
2100%
+ 2 programs with unclassified modality

Competitive Landscape

4 companies ranked by most advanced pipeline stage

MSD
MSDIreland - Ballydine
1 program
1
Quadrivalent Human PapillomavirusPhase 3
Sharp Therapeutics
Sharp TherapeuticsPA - Pittsburgh
1 program
1
Quadrivalent Human PapillomavirusPhase 31 trial
Active Trials
NCT00090220Completed3,819Est. Nov 2015
Shionogi
ShionogiJapan - Osaka
1 program
1
EnsitrelvirPhase 1Small Molecule1 trial
Active Trials
NCT06775730Completed24Est. Apr 2025
Servier
ServierFrance - Suresnes
1 program
1
VorasidenibPhase 1Small Molecule1 trial
Active Trials
NCT07235774Recruiting28Est. Mar 2026

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Sharp TherapeuticsQuadrivalent Human Papillomavirus
ServierVorasidenib
ShionogiEnsitrelvir

Clinical Trials (3)

Total enrollment: 3,871 patients across 3 trials

NCT00090220Sharp TherapeuticsQuadrivalent Human Papillomavirus

A Study to Evaluate the Safety, Immune Response, and Efficacy of Gardasil (V501, qHPV) in Mid-Adult Women (V501-019)

Start: Jun 2004Est. completion: Nov 20153,819 patients
Phase 3Completed
NCT07235774ServierVorasidenib

A Drug-drug Interaction Study of Vorasidenib and a Combined Oral Contraceptive in Healthy Female Participants

Start: Nov 2025Est. completion: Mar 202628 patients
Phase 1Recruiting
NCT06775730ShionogiEnsitrelvir

A Drug-Drug Interaction Study of S-217622 With Combined Oral Contraceptives in Healthy Adult Female Participants

Start: Dec 2024Est. completion: Apr 202524 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 3,871 patients
Small Molecule is the dominant modality (100% of programs)
4 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.